Clinical Trial Progress and Analyst Endorsement Spark Short-Term Rebound for Olema Pharmaceuticals

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) is one of the 11 Best Short-Term Stocks to Invest in.

The company sees its Buy rating reiterated following promising results from its clinical trials, including the VERITAC-2 trial.

A close-up of a pharmacist in a gleaming white labcoat holding a vial of biopharmaceuticals.

Headquartered in California, Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapies for women’s cancers. Its lead product candidate, palazestrant (OP-1250), is an estrogen receptor (ER) antagonist and degrader being evaluated in clinical trials for breast cancer. The company also has another drug candidate, OP-3136, a KAT6 inhibitor, in Phase 1 clinical trials.

In its Q1 earnings report, released on May 13, 2025, the company announced that the OPERA-02 trial for palazestrant and ribociclib in breast cancer is on track for initiation in 2025. The OPERA-01 monotherapy trial also continues, with results expected in 2026. Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) has further promising results in clinical data for OP-3136 in multiple cancer types.

Additionally, the company’s trials on VERITAC-2 showed that the drug is more effective for metastatic breast cancer with ESR1 mutations, as it improves survival with a good safety profile. Following these developments, H.C. Wainwright reiterated the Buy rating on the stock while maintaining the price target of $28.00.

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) is showing a potential short-term rebound, gaining 7.19% this week despite a decline of 67.38% over the past year, attracting the interest of short-term investors.

READ NEXT: 12 Best REIT Stocks to Buy Right Now and 10 Stocks with Huge Catalysts on the Horizon

Disclosure. None.